cerrar
Tagged with USA

Matt Eyles – President & CEO, Association of…
Matt Eyles, president and CEO of the Association of Healthcare Insurance Providers (AHIP) outlines how the US health insurance landscape has evolved…

FDA Drugs Approved in 2019
In 2019, the US FDA's Center for Drug Evaluation and Research approved 42 novel drugs, down from 59 drugs approved in 2018. Novartis had four drugs…

180-Day Exclusivity: The Key Ingredient in Hatch-Waxman
The AAM's Chip Davis looks back on 35 years of healthcare system savings from generic pharmaceuticals in the US, and the peril the generics industry…

Want to Change Healthcare? Coalitions are Key
Carla Smith looks at the three vital components behind successful strategic alliances in US healthcare:disruption,  data-driven demands and…

Samir Khalil – Executive Director, PhRMA Middle East &…
Samir Khalil, executive director for the Pharmaceutical Research and Manufacturers of America (PhRMA) Middle East and Africa (MEA), reveals why the US…

The Fight Against Superbugs Heats Up
Boston University School of Law’s Kevin Outterson* looks at how cost-saving measures are contributing to the rise of drug-resistant “superbugs”…

The Role of Patient Associations in Rare Disease Drug Development
Monica Weldon, CEO and president of Bridge the Gap – SYNGAP Education and Research Foundation, shares her recent experience at the US Drug Law and…

US FDA’s Efforts to Advance the Development of Gene Therapy
Peter Marks, director of the US FDA's Center for Biologics Evaluation and Research, outlines how the organization is attempting to further promote the…

Biosimilars Work. Why Aren’t They Taking Off in the US?
The AAM’s Chip Davis examines the roadblocks to greater adoption of biosimilar drugs in the USA, and why they need to be removed to potentially save…

Three Basic Truths About the US Healthcare System
AstraZeneca's Rick R. Suarez looks at workable solutions to the challenges facing healthcare in the US and why inter-stakeholder collaboration, rather…

Debbie Hart – Founding President & CEO, BioNJ, USA
BioNJ’s president and CEO Debbie Hart reflects on the association’s mission of creating a robust and engaging life sciences ecosystem in New…

Cybersecurity: A Health Business Risk Requiring Executive…
Carla Smith looks at the various cybersecurity risks that exist across the US healthcare continuum and the steps that executive leadership can take to…
We use cookies to ensure that we give you the best experience on our site. For more info

See our Cookie Privacy Policy Here